| A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer (NCT05275673) | Faeth Therapeutics | 2022-07-21 |
| A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC (NCT04976647) | Shanghai Henlius Biotech | 2022-01-18 |
| Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC (NCT05243355) | Qilu Hospital of Shandong University | 2021-12-03 |
| A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies (NCT05123482) | AstraZeneca | 2021-10-18 |
| Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (NCT04736173) | Arcus Biosciences, Inc. | 2021-02-08 |
| A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer (NCT04432207) | Imugene Limited | 2020-11-30 |
| Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (NCT04262856) | Arcus Biosciences, Inc. | 2020-05-28 |
| A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung (NCT04552535) | Boehringer Ingelheim | 2020-05-08 |
| Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer (NCT04073537) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-10-31 |
| A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC (NCT04033354) | Shanghai Henlius Biotech | 2019-08-14 |
| Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies (NCT04149691) | Celon Pharma SA | 2019-07-19 |
| Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC) (NCT03319316) | European Organisation for Research and Treatment of Cancer - EORTC | 2018-11-01 |
| Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC (NCT03717155) | Merck KGaA, Darmstadt, Germany | 2018-10-30 |
| Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial) (NCT03542461) | Gruppo Oncologico Italiano di Ricerca Clinica | 2017-09-25 |
| A Study to Assess the Efficacy and Safety of ABTL0812 (NCT03366480) | Ability Pharmaceuticals SL | 2016-12-01 |
| Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer (NCT02924233) | Symphogen A/S | 2016-11-01 |
| Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU) (NCT02996214) | Nanjing Luye Sike Pharmaceutical Co., Ltd. | 2016-11-01 |
| A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131] (NCT02367794) | Hoffmann-La Roche | 2015-06-11 |
| AZD2014 and Weekly Paclitaxel in Squamous NSCLC (NCT02403895) | AstraZeneca | 2015-04-15 |
| A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology (NCT02204345) | Hoffmann-La Roche | 2014-10-01 |
| Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NCT02106546) | AbbVie | 2014-04-10 |
| A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations (NCT02109016) | Clovis Oncology, Inc. | 2014-04-01 |
| Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients (NCT01911325) | Novartis Pharmaceuticals | 2013-10-01 |
| A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (NCT01763788) | Eli Lilly and Company | 2013-05-07 |
| A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NCT01769391) | Eli Lilly and Company | 2013-01-01 |
| Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (NCT02475382) | Bristol-Myers Squibb | |